<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03874936</url>
  </required_header>
  <id_info>
    <org_study_id>SO_SH_01_2019</org_study_id>
    <secondary_id>2019_000402_30</secondary_id>
    <nct_id>NCT03874936</nct_id>
  </id_info>
  <brief_title>The Effect of Perioperative Dexamethasone Administration on Postoperative Pain in Patients Undergoing Periacetabular Osteotomy.</brief_title>
  <acronym>PAODEX</acronym>
  <official_title>The Effect of Perioperative Dexamethasone Administration on Postoperative Pain in Patients Undergoing Periacetabular Osteotomy: A Randomised Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense Patient Data Explorative Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator-initiated, Danish mono-center, randomized, placebo-controlled,
      parallel group, double-blind, superiority trial of dexamethasone on postoperative pain
      management on patients undergoing operation for hip dysplasia with the periacetabular
      osteotomy procedure (PAO). 90 adults undergoing PAO will be enrolled.

      The primary outcome is to compare the effect of dexamethasone relative to placebo on
      cumulated postoperative morphine consumption at 48 hours.

      Key secondary outcomes include comparing the effect of repeated doses of dexamethasone
      relative to a single dose on cumulated postoperative morphine consumption at 48 hours, and to
      determine if dexamethasone is superior to placebo for: Perception of pain intensity,
      prevalence and degree of postoperative nausea and vomiting, and patient-reported outcome
      measures.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulated postoperative morphine consumption in milligrams after 48 hours.</measure>
    <time_frame>0-48 hours postoperatively</time_frame>
    <description>Morphine administered both as patient-controlled analgesia (PCA) i.v. morphine and any other supplemental morphine administered postoperatively. Consumption in mg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain intensity after 48 hours.</measure>
    <time_frame>24, 48 hours postoperatively</time_frame>
    <description>Pain is evaluated at rest and under the timed-up-and-go (TUG) procedure. Pain intensity is assessed using the visual analogue scale (VAS) (0-100mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulated postoperative morphine consumption from 48 hours until day 14 post operation</measure>
    <time_frame>48 hours - day 14 postoperatively</time_frame>
    <description>Morphine consumption in milligrams after the operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>24 and 48 hours postoperatively</time_frame>
    <description>Nausea and vomiting are evaluated using a 4 point scale: none, mild, moderate, severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiemetic consumption</measure>
    <time_frame>0-48 hours postoperatively</time_frame>
    <description>Evaluation of cumulated antiemetic consumption in mg and drug will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep</measure>
    <time_frame>0-7 days postoperatively</time_frame>
    <description>Sleep quality will be assessed using the VAS scale (0-100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed up and go test</measure>
    <time_frame>24, 48 hours postoperatively</time_frame>
    <description>Is assessed from; the time that the participant takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events (SAE)</measure>
    <time_frame>0-8 weeks after operation</time_frame>
    <description>SAE's including wound infection treated with antibiotics or revision. Patients will be asked for SAE during the intervention period, at a follow-up visit 8 weeks the operation. This will be supplemented with a look up for prescriptions.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cumulated postoperative morphine consumption in milligrams after 24hours.</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <description>Morphine administered both as patient-controlled analgesia (PCA) i.v. morphine and any other supplemental morphine administered postoperatively. Consumption in mg.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cumulated antiemetic consumption</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <description>antiemetic consumption in mg and drug will be assessed after 24hrs.</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>0 hours, 6 hours, 24 hours, 48 hours (72 hours)</time_frame>
    <description>assessment of fasting blood glucose in mg/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>0, 6, 24, 48 hours (72 hours) postoperatively</time_frame>
    <description>blood sample to evaluate the influence of dexamethasone on the postoperative inflammation development.</description>
  </other_outcome>
  <other_outcome>
    <measure>Leucocytes</measure>
    <time_frame>0, 6, 24, 48 hours (72 hours) postoperatively</time_frame>
    <description>blood sample to evaluate the influence of dexamethasone on the postoperative inflammation development.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cytokines</measure>
    <time_frame>0, 6, 24, 48 hours (72 hours) postoperatively</time_frame>
    <description>evaluate the decrease of cytokines concentration (Interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF) and pentraxin 3 (PTX3) as markers of response during treatment with Dexamethasone</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient reported outcome measure, quality of life</measure>
    <time_frame>3, 6, 12 months postoperatively</time_frame>
    <description>Based on the questionnaire: EuroQol - 5 Dimensions (EQ-5D) after 3 and 6 months and 1 year follow up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient reported outcome measures, health</measure>
    <time_frame>3, 6, 12 months postoperatively</time_frame>
    <description>Patient evaluated health based on the questionnaire: University of California, Los Angeles (UCLA) after 3 and 6 months and 1 year follow up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient reported outcome measures, the Oxford Hip questionnaire</measure>
    <time_frame>3, 6, 12 months postoperatively</time_frame>
    <description>Patient evaluated activity and pain, based on the questionnaire: Oxford Hip after 3 and 6 months and 1 year follow up.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Dexamethasone</condition>
  <condition>Hip Dysplasia</condition>
  <condition>Postoperative Pain</condition>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>A; Dexamethasone twice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24mg intravenous Dexamethasone (Dexavital®, Vital Pharma) 4mg/ml just before the operation and repeated after 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B; Dexamethasone once</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24mg intravenous Dexamethasone just before the operation and placebo which is 6ml of isotonic sodium chloride (9mg/ml, 'normal' saline) after 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C; Placebo twice</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo intravenous just before the operation and repeated after 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 24mg Solution for Injection</intervention_name>
    <description>Administrated i.v.</description>
    <arm_group_label>A; Dexamethasone twice</arm_group_label>
    <arm_group_label>B; Dexamethasone once</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution for Injection</intervention_name>
    <description>administrated i.v.</description>
    <arm_group_label>B; Dexamethasone once</arm_group_label>
    <arm_group_label>C; Placebo twice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing PAO due to symptomatic hip dysplasia (CE&lt;25grader) or retroverted
             acetabulum (crossover and posterior wall sign)

          -  ≥ 18 years

          -  Females if fertile: Verified negative human chorionic gonadotropin (HCG), usage of
             safe contraceptives or surgical sterilisation.

          -  Patients who give their written informed consent to participating in the trial, after
             having fully understood the content of the protocol and restrictions.

        Exclusion Criteria:

          -  Patients who cannot speak or understand Danish

          -  Allergy or contraindications to trial medication

          -  Spinal anaesthesia

          -  Second intervention carried out simultaneously (e.g. femur osteotomy)

          -  Patients with daily opioid consumption prior to surgery (tramadol and codeine
             accepted)

          -  Drug, medical abuse or weekly alcohol consumption beyond ≥7 (female) and ≥14 (men)
             units, respectively.

          -  Mental disability, anxiety disorder (active psychiatric disorder or consumption of
             tricyclic antidepressants)

          -  Diabetes diagnosed prior to inclusion

          -  Immune suppression therapy (e.g. systemic glucocorticoids)

          -  Kidney impairment (eGFR &lt; 50ml/min) or liver disease (≥Child Pugh B)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Søren Overgaard, Professor, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Orthopaedic Surgery, Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stine Hebsgaard, MD</last_name>
    <phone>26814697</phone>
    <phone_ext>+45</phone_ext>
    <email>stine.hebsgaard3@rsyd.dk</email>
  </overall_contact>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Stine Hebsgaard</investigator_full_name>
    <investigator_title>medical doctor, principal investigator</investigator_title>
  </responsible_party>
  <keyword>postoperative pain</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>pain management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hip Dislocation</mesh_term>
    <mesh_term>Hip Dislocation, Congenital</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

